The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina

Clinical Research in Cardiology

Volumn 101, Issue 7, 2012, Pages 585-591

  Tendera, Michal ^a   Gaszewska Zurek, Ewa ^a   Parma, Zofia ^a   Ponikowski, Piotr ^b   Jankowska, Ewa ^b   Kawecka Jaszcz, Kalina ^c   Czarnecka, Danuta ^c   Krzemińska Pakuła, Maria ^d   Bednarkiewicz, Zbigniew ^d   Sosnowski, MacIej ^a   Kilama, Michael Ochan ^e   Agrawal, Rahul ^f  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e Bayer Health Care   (Italy)

^f BAYER PHARMA AG   (Germany)

Author keywords

A1 receptor agonists; Capadenoson; Coronary artery disease; Exercise testing; Heart rate; Stable angina

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST; CAPADENOSON; NEW DRUG; PLACEBO;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXERCISE TOLERANCE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME; VERTIGO; WORKLOAD;

ADENOSINE A1 RECEPTOR AGONISTS; ADMINISTRATION, ORAL; ADULT; AGED; AMINOPYRIDINES; ANALYSIS OF VARIANCE; ANGINA, STABLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; HEART RATE; HUMANS; MALE; MIDDLE AGED; POLAND; RECEPTOR, ADENOSINE A1; SEX FACTORS; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863726071     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-012-0430-8     Document Type: Article

References (20)

1. Fox K, Garcia MAA, Ardissino D et al (2006) Task force on the management of stable angina pectoris of the European Society of Cardiology. Guidelines for the management of stable angina pectoris. Eur Heart J 27:1341-1381
2. Borer JS, Fox K, Jaillon PP, Lerebours G (2003) Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina. A randomized, double-blind, multicentered, placebocontrolled trial. Circulation 107:817-823
3. Tardif JC, Ford I, Tendera M, Bourassa MG, INITIATIVE Investigators (2005) Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529-2536
4. Liu Y, Yang X, Yang XM, Walker S, Förster K, Cohen MV, Krieg T, Downey JM (2010) AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts. Basic Res Cardiol 105:129-137
5. Koester R, Kaehler J, Meinertz T (2011) Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol 100:121-126
6. Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T (2010) Ivabradine with combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol 99:665-672
7. Hjalmarson A, Gilpin EA, Kjekshus J et al (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65:547-553
8. Fox K, Ford I, Steg PG, Tendera M, Robertson M, BEAUTIFUL investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817-821
9. Yan L, Burbiel J, Maass A, Mueller CE (2003) Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8:537-576
10. Belardinelli L, Shryock J, Song Y, Wang D, Srinivas M (1995) Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 9:359-365
11. Dhalla A, Shryock J, Shreenivas R, Belardinelli L (2003) Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 3:369-385
12. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM (1991) Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84:350-356
13. Auchampack JA, Gross GJ (1993) Adenosine A1 receptors, KATP channels and ischaemic preconditioning in dogs. Am J Physiol 264:H1327-H1336
14. Zablocki JA, Wu L, Shryock J, Belardinelli L (2004) Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation. Curr Top Med Chem 4:839-854
15. Frey R, Mueck W, Delesen H (2006) Single dose, basic phase I dose-escalation study in a randomized, single-blind, placebocontrolled, group comparison design to investigate safety and tolerability of BAY 68-4986 and its pharmacodynamics and pharmacokinetics after oral dosing in 8 healthy male subjects per dose step. Internal Archive, Report Number PH-34381
16. Shewan LG, Coats AJ (2010) Ethics in the authorship and publishing of scientific articles. Int J Cardiol 144:1-2
17. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G (1999) A1 and A3 adenosine receptor agonists: an overview. Exp Opin Ther Patents 9:515-527
18. Elzein E, Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17:1901-1910
19. Higgins MJ, Hosseinzadeh H, MacGregor DG, Ogilvy H, Stone TW (1994) Release and actions of adenosine in the central nervous system. Pharm World Sci 16:62-68
20. Press NJ, Gessi S, Borea PA, Polosa R (2007) Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opin Ther Pat 17:979-991